Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

Navajo -good point
Todays news is great -they have stated that more large pharmas are to take delivery of PSD401 - means more product revenues -thats what we want to hear.
Notice they haven't stated the Pharmas name or deal amount -I wonder if its the same company who they will announce the deal for PSD502 with? interesting.

PSD401 is apparently due for many deliveries in Q1 2007.

BTW, Hondaman, since you asked me for tips: Just want to let you know I have been persuaded to join the GTL club. This is the ethanol producer - they have big plans for growth and will soon be producing far more than RVA, which currently has a bigger market cap. New plant due to start commercial production in early December; capacity will then double as they extend the plant over the following year or so, plus they want to build a further three plants. Shares Mag has tipped it consistently this year.

Prospects for growth look excellent, but please DYOR, etc.

Anyone think this company will produce a deal by Christmas?

The suspense is killing me.

RNS out on 4th Dec - I missed it because I was too busy watching SOLA, but it's more good press for PLE!

Plethora Solutions - Product Update - ErecAid
RNS Number:2428N
Plethora Solutions Holdings PLC
05 December 2006


PLETHORA SOLUTIONS HOLDINGS PLC

Product Update

Osbon ErecAid(R): Use of ErecAid after Radical Prostate Surgery reduces
incidence of penile shortening.

Plethora Solutions Holdings plc ('Plethora', AIM: PLE), the specialist developer
of products for the treatment and management of urological disorders, notes the
publication of new research that shows that regular use of the Osbon ErecAid(R)
product marketed through Plethora's US subsidiary, Timm Medical, can reduce the
incidence of penile shortening in men recovering from prostate cancer surgery; a
procedure known as radical prostatectomy ('RRP').

An estimated 235,000 American men will be diagnosed with prostate cancer in 2006
(1), of which approximately 25% will be treated by having their prostate
surgically removed via a radical prostatectomy. Consequent tissue and nerve
damage and scar formation can lead to temporary or sometimes permanent loss of
erectile function and changes in penile dimension. Penile shrinkage occurs in
more than two-thirds of men undergoing radical prostatectomy, with reductions in
length of more than 1cm reported in almost half of men three months after
surgery(2),(3)

In a paper entitled 'Preservation of Penile Length After Radical Prostatectomy
(RRP): Early Intervention With a Vacuum Erection Device (VED)' presented at the
7th Annual Society of Urologic Oncology on December 1, 2006, Dr. Bruce Dalkin
reported that of the 28 men recovering from radical prostatectomy who made daily
use of the Osbon ErecAid(R) vacuum system, only one experienced a reduction in
penile length greater than 1cm. Of the four patients who did not make daily use
of the vacuum system, three experienced a reduction in penile length of more
than 1cm. The incidence of penile shrinkage in the experimental group of 3.5%
compared favorably to 48% incidence of penile shortening after RRP reported in
historical controls(2).

The study concludes that '...early intervention with VED should be recommended
in all potent men undergoing nerve-sparing RRP to preserve penile length.'


Dr Steven Powell, Plethora CEO, commented:

'The Osbon ErecAid(R) is frequently prescribed for patients for whom oral drugs
are ineffective treatments for erectile dysfunction. This new research
highlights the potential for the ErecAid(R) device to play a significant role in
minimising the impact of radical prostate surgery on a patient's quality of
life.'

--------------------------
(1) American Cancer Society 2006

(2) Munding MD, Wessells HB, Dalkin BL.Pilot study of changes in stretched
penile length 3 months after radical retropubic prostatectomy. Urology 2001;58:
567-93

(3) Savoie M, Kim SS, Soloway MS.A prospective study measuring penile length in
men treated with radical prostatectomy for prostate cancer. J Urol2003; 169 :
1462-44

-Ends-

chart is far from encouraging ..... on that basis, i would not be a buyer

It's the potential for a Phse III trials deal and/or takeover that makes this one appealing.

You might not like the shares, but are you able to provide a product review?? ;o)

nope .... never even heard of the company

:o)

wish I had bought SOLA -nevermind -I can see Plethora doing the same -broker has already given a target of 5+ on Plethora but I can see this going well above that because all their products have been given FDA approval whereas top Pharmas are struggling to get this which puts Plethora in a great position.
Their products have billions of market potential. I reckon by end of 2007 this company will be bought out and I am putting a 10 tag/share based on fundamentals. They have a revenue stream from Timm Medicals.
Neutech Pharma was bought out at 10+ and there are many similarities in number of shares in issue etc. I am happy with the top guys in the management as they know their stuff and have worked in top Pharmas and have the right connections.The top PLE scientist has 80 Patents+ to his name including Viagra which he commercialised at Pfizer.
I am gonna sit tight -see you all on deal news which I expect will double the price and more onwards. I still expect before year end although am happy whenever it arrives as the deal can only get bigger.

soul traders I wish you had forced me to buy some SOLA shares at 2 or so!!!
Infact did you buy any for me?

Honda, I did buy some for you, but as I was on the way to deliver them to you, I sold them for myself :o)

LOL!!

A disappointing year in terms of progress in the shareprice.
Although looking at the fundamentals especially with Timm Medicals and PSD401 bringing in great revenues this will do itself justice next year with the news data from so many products and with licensing deals. No doubt they want to do a deal to speed up phase III of PSD502 ,also the PSD502 product can now be licensed as an asset as it has wound pain relief application as well as for PE so any deal for the asset will be large no doubt.
Next year will be very interesting imho and in the next results they should be in profit and with the deal well well above in profit. The top man Mr Evans of Merlin Sciences has also stated that Plethora Solutions will certainly be one of the companies that will be taken over by cash rich USA Pharmas.
I shall wait for that bid can't see it being less than 10 meself and that'll be worth the wait.

It would be great if they could pull their finger out . . . !!

(Yawn)

RNS out today:

Plethora Solutions - Clinical Update
RNS Number:9118Q
Plethora Solutions Holdings PLC
08 February 2007


PLETHORA SOLUTIONS HOLDINGS PLC

Clinical Programme Extension - Plethora initiates parallel study for PSD597 as
analgesic therapy in urogynaecological procedures.

Plethora Solutions Holdings PLC ('Plethora', AIM : PLE), the specialist
developer of products for the treatment and management of urological disorders,
announces the initiation of a new clinical programme in an additional clinical
indication for PSD597, a novel therapy under development for the treatment of
interstitial cystitis and painful bladder syndrome (IC/PBS).

Following positive feedback from the clinical centres involved in its existing
IC study, Plethora has, in parallel, initiated a second study to demonstrate
efficacy of the product as an analgesic therapy in urogynaecological procedures
such as cystoscopy and bladder biopsy. These procedures are often performed
currently in the absence of any analgesic agent. As a result of its fast onset
of action, PSD597 may bring immediate pain relief to these patients during this
short procedure. It has been estimated that at least 62,000 Americans undergo a
bladder biopsy each year to confirm the presence of bladder cancer, while over
150,000 women undergo hydrodistension procedures for IC/PBS. Recruitment is
already under way in five centres in this second PSD597 study, which is
scheduled to report in the first half of 2007.

PSD597 is currently undergoing a Phase II clinical study in North America to
demonstrate its efficacy in the treatment of interstitial cystitis; a chronic
syndrome characterised by bladder pain and increased urinary frequency and
urgency. A self-reported survey of American households indicated that almost 1%
of women had received a diagnosis of IC/PBS suggesting that there are at least
900,000 female sufferers in the USA alone. Current treatments for IC/PBS are
limited in their effectiveness. The objective of the ongoing clinical programme
is to provide additional confirmation of the findings from two pilot studies in
which PSD597 was shown to provide immediate, effective and long-acting symptom
relief in these major, poorly-controlled, debilitating conditions. Recruitment
in this current Phase II study is on track to report results in the first half
of the year.

Professor Alvaro Morales of Queens University, Ontario, Canada commented:
'Based on the degree of benefit and duration of clinical effect emerging in the
current IC study together with the results of the previous two previous studies,
PSD 597 could be of considerable benefit to patients suffering not only from
chronic IC and bladder pain but also in this second area of un-met clinical
need'.

Dr Steven Powell, Plethora CEO, concluded:
'Existing, published clinical data for the efficacy of PSD597 in the treatment
of IC is promising and we have already received a strong level of interest in
this product from potential partners. The development path for the new,
additional indication is short as the product would be used in an acute setting
with no long term safety issues. We may therefore be in a position to consider
retaining marketing rights to the second indication whilst continuing partnering
discussions around the primary, IC/PBS indication'.

-Ends-

Plethora seems to be good at finding secondary applications for its products. The new application for PSD597 ought to be a winner in market terms, IMO, as long as the drug itself is proved safe and effective.

It would be nice to hear news of a deal on the PE treatment, though!!

WDIK, PDYOR, etc.

More progress (at last)

Plethora Solutions Holdings PLC ('Plethora', AIM : PLE), the specialist
developer of products for the treatment and management of urological disorders,
has announced that it has filed an Investigational New Drug (IND) application
with the FDA to initiate the final phase of clinical development of PSD502, a
product for the treatment of premature ejaculation. This follows positive
outcomes from meetings with regulatory authorities in both the USA (FDA) and
Europe (MHRA) which have defined the clinical development programme required to
take this project to marketing authorisation.

As announced previously, Plethora is in the advanced stage of partnering
discussions for PSD502. Having reviewed the PSD502 development plans with
potential development and marketing partners, Plethora has now completed its
filing with the FDA ahead of moving the product into Phase III once partnering
agreements have been concluded.

This is another key step towards the commercialisation of PSD502 and follows the
recent conclusion of a manufacturing and supply agreement between the company
and Inyx Inc of New York, USA. Under the terms of this agreement, Plethora has
secured supply of PSD502 both for the Phase III study and any subsequent
potential commercial requirements.

PSD502 is a proprietary formulation of two marketed drugs, lidocaine and
prilocaine, dispensed by a metered dose aerosol developed for the treatment of
premature ejaculation, a disorder affecting up to 30% of men in Europe and the
USA and for which there is no approved treatment. The product is applied locally
when needed (often referred to as 'on demand' therapy) and is effective within
five minutes. Other key advantages of the product are a minimal risk of safety
issues, minimal partner transfer eliminating the need to use a condom and the
potential for the dose to be self titrated or adjusted under physician
direction. The product was shown to increase ejaculation latency time
substantially when compared with placebo in a multi-centre Phase II study. This
data has been published recently in BJU International (Dinsmore W et al 2007
BJU int 99: 369-35)

The programme to secure product registration in the USA and Europe will involve
less than 600 patients and could be completed within 15 months. This residual
development programme reflects both the excellent efficacy data generated by
Plethora to date and the extensive historical clinical safety database available
on the components of PSD 502. The suitability of this development programme has
been confirmed via recent meetings with the FDA and the European authorities
(MHRA).

The design and structure of the Phase III study has also been discussed
extensively with potential marketing partners. The combined worldwide Phase III
programme will involve in the region of 20 European and 20 North American
centres and will be supported by Plethora and its future development marketing
partners.

Professor Culley Carson of the University of North Carolina and a past president
of the Sexual Medicine Society of North America (SMSNA) stated 'The fact the
regulatory authorities require relatively little additional safety data would
appear to vindicate Plethora's approach of using a product that does not result
in systemic exposure. Given the proposed track of the programme, welcome relief
for the many hundreds of thousands of PE sufferers is in sight at last.'

Steven Powell, Plethora CEO, concluded:

'We are pleased to be advancing PSD502 into the final phase of clinical
development for treatment of premature ejaculation. With the relatively short
development path to registration and the proximity to securing partnering
agreements these are exciting times for Plethora'.

-Ends-

Nav, well done for beating me to the post!

Good news - and about time we had an update, too!

With 20 centres in the US and another 20 in Europe, there is clearly quite a lot of work involved with the Phase III trial, so maybe that explains the delay.

Hope to see this rocket when the partnership deal is announced.

PLE Bid: 180p Offer: 187p Change: 3 Only 7,000 or so traded, though.